HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice

doi:10.3748/wjg.v10.i23.3506

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4020)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

599

HTML

2965

Figures (1-4)

274

Tables (1-1)

182

Sum=4020

Dec 1, 2004 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (44)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Dec 1, 2004; 10(23): 3506-3510
Published online Dec 1, 2004. doi: 10.3748/wjg.v10.i23.3506

Full Size Figure Download Figure

Figure 2 Cholangiography, CT, or US before and after intraluminal brachytherapy. A: Bile duct dilation of left lobe caused by cholangiocarcinoma was shown by CT (arrow). B: Cholangiography showed hilar stricture (arrow). C: Intraluminal brachytherapy (fractional dose 7 Gy, total dose 21 Gy) was performed after an 8 mm×60 mm SMART stent insertion. D: CT follow-up 11 mo after intraluminal brachytherapy showed no progress of the tumor and no redilation of the bile duct (arrow).

Citation: Chen Y, Wang XL, Yan ZP, Cheng JM, Wang JH, Gong GQ, Qian S, Luo JJ, Liu QX. HDR-¹⁹²Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol 2004; 10(23): 3506-3510
URL: https://www.wjgnet.com/1007-9327/full/v10/i23/3506.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i23.3506